StockData
Starling Oncology, Inc. logo

Starling Oncology, Inc. (STLN) stock

STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$3.40−0.14 (-3.95%)

Close on Nov 17, 2026Market cap $346.52MP/E –Yield –

Starling Oncology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Starling Oncology's operating cash flow for the twelve months ending Sep 30, 2026 was $23.10M. For fiscal 2025 it was -$24.59M. The highest annual figure on record is $508.00K in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.59M–
FY2024Dec 31, 2024-$26.54M–
FY2023Dec 31, 2023-$36.32M–
FY2022Dec 31, 2022-$61.76M–
FY2021Dec 31, 2021-$32.68M-6533.1%
FY2020Dec 31, 2020$508.00K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$10.14M–
Q2 FY2026Jun 30, 2026$11.94M–
Q1 FY2026Mar 31, 2026-$2.22M–
Q4 FY2025Dec 31, 2025$3.23M-19.2%
Q3 FY2025Sep 30, 2025-$12.63M-1642.1%
Q2 FY2025Jun 30, 2025-$10.20M–
Q1 FY2025Mar 31, 2025-$4.99M–
Q4 FY2024Dec 31, 2024$4.00M–
Q3 FY2024Sep 30, 2024$819.00K–
Q2 FY2024Jun 30, 2024-$15.66M–
Q1 FY2024Mar 31, 2024-$15.88M–
Q4 FY2023Dec 31, 2023-$3.89M–
Q3 FY2023Sep 30, 2023-$8.31M–
Q2 FY2023Jun 30, 2023-$8.66M–
Q1 FY2023Mar 31, 2023-$15.45M–
Q4 FY2022Dec 31, 2022-$14.00M–
Q3 FY2022Sep 30, 2022-$20.40M–
Q2 FY2022Jun 30, 2022-$10.38M–
Q1 FY2022Mar 31, 2022-$16.98M-3759.7%
Q4 FY2021Dec 31, 2021-$23.34M-2412.8%
Q3 FY2021Sep 30, 2021-$2.68M–
Q2 FY2021Jun 30, 2021-$7.13M–
Q1 FY2021Mar 31, 2021$464.00K–
Q4 FY2020Dec 31, 2020$1.01M–
Q3 FY2020Sep 30, 2020-$69.42K–
Q2 FY2020Jun 30, 2020-$402.77K–
Q1 FY2020Mar 31, 2020-$28.75K–

More Starling Oncology figures

See a number that looks wrong?